Australia is eagerly awaiting the availability of Retatrutide, a novel medication by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, has shown significant efficacy in clinical trials, https://rebeccaqiem151486.ourabilitywiki.com/11066390/novo_nordisk_s_retatrutide_australia_a_promising_advancement_for_weight_management